🟢 Abcellera Biologics is trading 4.15% up today after pricing an oversubscribed $200 million public offering

Abcellera Biologics is trading 4.15% up now at $10.79 after pricing an oversubscribed public offering expected to generate approximately $200 million in gross proceeds.

• The financing will support its internal pipeline, including ABCL635, following positive Phase 2 menopause-treatment results.
• The offering includes 17,435,897 shares priced at $9.75 and pre-funded warrants.
• Closing is expected August 14, 2026.